New trial aims to boost survival in HER2+ breast cancer by adding surgery and radiation to drug therapy

NCT ID NCT07578116

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase III trial is for people with HER2-positive stage IV breast cancer that has spread to a limited number of spots (oligometastatic). It tests whether adding surgery and focused radiation to standard drug therapy helps them live longer or delays cancer growth compared to drug therapy alone. About 562 participants will be randomly assigned to receive either standard systemic therapy alone or standard therapy plus locoregional treatment (surgery and radiation) and metastasis-directed radiation. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Surgery, radiation therapy, and stereotactic body radiation therapy (SBRT)

What this could lead to

If it works, this could show that adding focused treatments like surgery and radiation to standard drug therapy helps people with HER2+ breast cancer that has spread to a few spots live longer or keep the cancer from growing.

What could go wrong

This is a large phase III trial, but it hasn't started yet. Adding surgery and radiation may not improve survival over standard therapy alone, and these procedures carry risks like infection, pain, or damage to nearby tissues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.